Warm Mathias, Kates Ronald, Mallmann Peter, Dick Michèlle, Nawroth Frank, Harbeck Nadia, Paepke Stefan, Thomas Anke
Department of Senology, University of Cologne, Germany.
Anticancer Res. 2007 Mar-Apr;27(2):1031-8.
The objective of this study was to determine the predictive impact of several established tumor biological factors (progesterone receptor, estrogene receptor, HER2/neu, and Ki-67) on response to pre-operative combination chemotherapy with epirubicin and paclitaxel in a representative group of primary breast cancer patients.
Thirty-eight primary breast cancer patients (metastasis-negative) received pre-operative chemotherapy with epirubicin and paclitaxel. The response characteristics analyzed included pathological complete response and partial remission determined by 3D ultrasound, as well as down-staging and breast conserving surgery.
Pathologically complete response occurred in six patients. Overexpression of HER2/neu, low (negative) hormone receptors and high Ki-67 were all significant positive predictive factors for response to pre-operative chemotherapy.
HER2/neu overexpression is predictive for response not only to trastuzumab, but also to epirubicin and paclitaxel.
本研究的目的是确定几种已确立的肿瘤生物学因素（孕激素受体、雌激素受体、HER2/neu和Ki-67）对一组具有代表性的原发性乳腺癌患者术前使用表柔比星和紫杉醇联合化疗反应的预测影响。
38例原发性乳腺癌患者（无转移）接受了表柔比星和紫杉醇的术前化疗。分析的反应特征包括通过三维超声确定的病理完全缓解和部分缓解，以及降期和保乳手术。
6例患者出现病理完全缓解。HER2/neu过表达、低（阴性）激素受体和高Ki-67均是术前化疗反应的显著阳性预测因素。
HER2/neu过表达不仅可预测对曲妥珠单抗的反应，还可预测对表柔比星和紫杉醇的反应。
